Pular para o conteúdo principal
Ranking Invest

BLRX - BioLineRx Ltd.

Segmento: HealthcareBioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Análise Ranking Invest

Valor de Mercado
$ 9.96 Mi
IVR
-7.56Índice proprietário de comparação relativa: -7,56.
IVR2
-9.61Leitura proprietária complementar: -961%.
MLL
-9.61Leitura proprietária complementar: -961%.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 20.86 Mi

Dívida Líquida

$ 4.71 Mi

L4T

-$ 3.40 Mi

MM4T

468.66%

Indicadores Básicos

ROE

-16.29%

Índices de Previsibilidade

Receita Líquida

G0.85

Lucro

D0.81

Margem

E1.23

Índices de Tendência

Receita Líquida

B7.81

Lucro

C2.63

Margem

F-4.59

Índices de Endividamento

DIV/PAT

0.23

DIV/L4T

-1.38

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.